C-Met immunoreactivity in operated stage I non-small cell lung cancer patients: Is it a prognostic marker?

Volume: 53 Number: 1 March 1, 2014
  • Ozdil A
  • Cakan A
  • Cagirici U
  • Turhan K
  • Ergonul A G
  • Veral A
Ege Journal of Medicine Cover
Ege Journal of Medicine
PDF Download
EN TR

C-Met immunoreactivity in operated stage I non-small cell lung cancer patients: Is it a prognostic marker?

Abstract

Aim: In this study we evaluated the correlation between c-Met immunoreactivity and survival, thus the effect of hepatocyte growth factor (HGF) on prognosis, in operated early-stage non-small cell lung carcinoma (NSCLC) patients. Materials and Methods: Seventy patients who underwent resection for stage IA or IB NSCLC were examined retrospectively. Pathological preparations were evaluated to investigate c-Met immunoreactivity. Those with normal bronchial epithelium in the sections were used as positive control group and the sections of those who had not been stained by primary antibody were regarded as the negative control group. C-Met immunoreactivities were determined according to scores of staining. Results: There were no significant differences between c-Met immunoreactivity and clinicopathological factors. The analysis after exclusion of large cell carcinoma cases showed that c-Met immunoreactivity was higher in adenocarcinomas than in squamous cell carcinomas and the difference was statistically significant. Survival analysis to estimate the prognostic significance of c-Met immunoreactivity showed no significant differences for both disease-free (p=0.499) and long-term survival (p=0.261). The difference between c-Met immunoreactivity and survival for the adenocarcinoma and squamous cell carcinoma groups was not significant. Conclusion: It seems that HGF expression and serum HGF levels appeared to be stronger prognostic markers than c-Met immunoreactivity for NSCLC, therefore detailed studies were needed regarding these prognostic factors.

Keywords

Details

Primary Language

Turkish

Subjects

-

Journal Section

-

Authors

Ozdil A

Cakan A

Cagirici U

Turhan K

Ergonul A G

Veral A

Publication Date

March 1, 2014

Submission Date

March 1, 2014

Acceptance Date

-

Published in Issue

Year 2014 Volume: 53 Number: 1

DOI

https://doi.org/10.19161/etd.344034

IZ

https://izlik.org/JA59PJ45FU

Cite

RIS / Bibtex
Vancouver
1.Ozdil A, Cakan A, Cagirici U, Turhan K, Ergonul A G, Veral A. Opere edilmiş evre I küçük hücreli dışı akciğer karsinomlu olgularda c-Met immünreaktivitesi: Prognostik bir belirteç mi? EJM. 2014 Mar. 1;53(1):13-8. doi:10.19161/etd.344034

Ege Journal of Medicine enables the sharing of articles according to the Attribution-Non-Commercial-Share Alike 4.0 International (CC BY-NC-SA 4.0) license.